

Our Partner in India

Mr Ramani Dorai, the owner of the Indian consulting company Hartec Consultants in Bangalore supports the park management in the acquisition and assistance of Indian companies. Mr Dorai has excellent



knowledge in the fields of health-care, pharmaceuticals, biotechnology, management education & training and information technology. He




cooperates closely with the Chamber of Industry and Commerce in Bangalore. As "our" representative on the spot he identifies Indian companies who are interested in gaining entry into the markets of Europe and in particular Germany. Following a comprehensive presentation of the Biotechnology Park Luckenwalde and of the possibilities of cooperation and sponsorship available in the State of Brandenburg he guides these companies and the park management in the discussions that follow all the way through to the successful founding of a branch in Luckenwalde. ■



Successful Trade Fair Participations in 2009

In 2009 the Biotechnology Park Luckenwalde was represented with a stand at the Biotechnica in Hannover, the ACHEMA in Frankfurt and at the Chemtech & Pharma-world 2009 in Mumbai. The Biotechnica and the ACHEMA are considered the leading European trade fairs in their respective fields. As well as presenting an overview of the industry, they primarily showcase a high number of international exhibitors who show great interest in the German and European markets. In this way, many interesting discussions can be conducted "on the spot" and contacts can be established regarding setting up a branch in the Biotechnology Park. "Both fairs completely lived up to our expectations. We expect new company locations over the course of the next few years, particularly from the Asian region, especially India", commented Christoph Weber, the Manager of the Biotechnology Park. With a growth rate of 12 to 20 % in 2008 the Indian pharmaceutical market expanded at an above average rate. This was also reflected in Chemtech & Pharma-

world, one of the most important Indian fairs in the field of chemical plant manufacturing and pharmaceutical equipment. Due to the worldwide recession and the strict immigration regulations applicable to the USA, Europe is increasing in its importance as a partner for Indian companies in the fields of research and development and of production. "We want to exploit these opportunities to the advantage of the Biotechnology Park Luckenwalde," says Christoph Weber. Following this fair, Mr Weber and Mr Engelhard travelled on to Bangalore. Through Mr Ramani Dorai, Biotechnology Park Luckenwalde's local consultant in India, further discussions were held with companies who had previously expressed their interest in locating their business in Luckenwalde. At the same time, existing contact with the company Firepro Systems Ltd. could be promoted further. This company intends to open a branch in Luckenwalde before the end of this year. ■



Excellent Traffic Connections

The attractiveness of the Biotechnology Park Luckenwalde's location in the Greater Berlin Area is to be enhanced yet further in 2010. The four-lane access road provided by the new, motorway-like B101 leading from Berlin Marienfelde via the A10-motorway junction "Ludwigsfelde Ost" to the "Biotechnologiepark" exit 500 m further down the road, makes driving quick and convenient. Work is to begin on the last remaining section this year. This will ensure fast access to the new Airport BBI (Berlin-Brandenburg-International) at Berlin-Schönefeld, in just 30 minutes. From 2011 onwards, direct flights worldwide will be taking off in the immediate vicinity.

An attractive proposition for investors with foreign customers! In the same way, local public transport also guarantees access to the centre of Berlin within 35 minutes by means of the Regional Express trains to and from Berlin Hauptbahnhof (Berlin Central Station) via the S-Bahn metropolitan railway at Südkreuz and Potsdamer Platz. The trains run every hour during the daytime and every half hour during the morning and evening rush hours. Luckenwalde could therefore almost be described as a suburb of Berlin. The attractions of the capital lie virtually on the doorstep. ■

BIOTECHNOLOGIEPARK



LUCKENWALDE

BIOLUCK '10



Successful certification of the Biotechnology Park Luckenwalde

The Biotechnology Park Luckenwalde maintains, develops and practises an accredited Quality Management System (QM-System) in accordance with the standard DIN EN ISO 9001:2008 and the EU-GMP Guidelines (Part I, Chapter 3) for the areas of premises and centralised technology. It is consequently the only technology park in the whole of Germany that has an accredited QM-System. On the occasion of the second reassessment undertaken on 01 December 2009 by the DQS GmbH, the system was judged to be fully functional. Those companies resident within the Biotechnology Park Luckenwalde that maintain a QM-System, such as Bioline GmbH, Biocyc GmbH & Co EntwicklungKKG, CellTrend GmbH, Chiracon GmbH or even LGC GmbH, are supported by the Park Management in the implementation thereof with regard to premises and centralised technology by the provision of technical documentation. In order to be able to successfully place their products and services on national and international markets, companies from the field of Life Sciences also have to operate a functioning QM-System. Such certification is thus becoming an essential criterion for success. ■

On Expansion Path!

A new settlement in the Biotechnology Park – 100 new jobs

With an investment volume of approx. EUR 45 million, Human BioSciences GmbH (HBS) is going to set up a new clean room facility in the Biotechnology Park Luckenwalde. The biotech company develops, manufactures and distributes collagen-based wound dressings and tissue-regenerating cosmetics. HBS possesses a licence from a US-biotech for a unique KollagenTM tech-

The new production facility has an overall area of approx. 8000 square metres including about 2000 square metres of clean room area as well as several research labs. HBS will collaborate with research partners in the biotech park and the life sciences cluster Berlin-Brandenburg to diversify its product portfolio. Beside R&D, administration and sales the approx. 100 new jobs



Future view of the building at the entrance to the Biotechnology Park.



The HBS ground-breaking ceremony in September 2009 with Brandenburg's Economic Minister, the District Administrator and the Mayoress

nology. In the USA these KollagenTM wound care products are already FDA approved and Medicare reimbursed. In particular patients with chronic wounds like diabetic foot or pressure ulcers and burn care patients can be helped with the superior and cost effective KollagenTM products.

The superior wound healing effect of KollagenTM products is based on the conservation of collagen's biological structure and function during the manufacturing process. The native collagen fibrils in KollagenTM wound care products support tissue regeneration in all phases of wound healing by their biological functionality. In the US, Taiwan and India these wound dressings are already in great demand, having 2-digit annual growth rates. HBS now exclusively introduces KollagenTM to Europe via its biotech facility in the state of Brandenburg – Germany's capital region.

will be mainly established in production and logistics. Semi-skilled workers from the region will profit from this after qualification in an appropriate training course. The Human BioSciences GmbH has already concluded a sales and distribution contract for the coming five years with a multinational company which guarantees capacity utilization well over 60 percent.

The HBS investment is not merely a leap forward in quality for the biotech park, but the entire life sciences cluster Berlin-Brandenburg will profit from the new player in regenerative medicine and its unique technology.

The State of Brandenburg and the Brandenburg Economic Development Board (ZAB) in particular have supported the HBS settlement project from day one most intensively with competent consultancy and appropriate funding. ■

10 Years of CellTrend GmbH - 10 years of growth generated from our own strength



Dear reader,

The Biotechnology Park Luckenwalde has earned itself a good reputation as a biotechnological location in the area surrounding our capital city. The initial scepticism as to whether it was a good idea to set up such an innovative centre outside Berlin has long since been proven groundless. Today, the Biotechnology Park enjoys an international reputation, and

December 1998, a "Storm and Stress" period on the German biotechnology scene: company foundations galore, a never-ending stream of risk capital. Today that all sounds like a fairy tale from a long-forgotten era. That was also the time of the founding of CellTrend, but the founding team was determined to retain its independence and to succeed in its own right, and thus turned down external capital. The correct decision, from today's perspective! "In the Biotechnology Park Luckenwalde we found excellently equipped laboratories, meaning that our investment requirement was low. This was an extremely important factor for our independence", so says the Managing Director, Dr Harald Heidecke. To this very day, CellTrend has retained its flexibility and freedom of action, and has fuelled the growth rates of the past 10 years from its own profits. This is appreciated by international customers from the pharmaceutical and biotechnological industries,

who send new potential ingredients to CellTrend in order to determine their biological activity, or who have hundreds of serum samples analysed in clinical studies. Finally, CellTrend offers comprehensive assistance in the fields of cell culture test systems and immunologic proofs (e.g. ELISA), including its own patent-protected human diagnostic systems. ■



Centre for Molecular Oncology

The "Centre for Molecular Oncology" is one of the most recent tenants to arrive at the Biotechnology Park. CellTrend GmbH has outsourced its individual patients' diagnostics into this newly founded company, and greatly expanded these activities.

In addition to molecular-biological biomarkers for the diagnosis and stratification of the carcinoma of the prostate gland, a multitude of genetic designations are on offer. The past few years have brought with them hitherto undreamt-of possibilities for the diagnosis and therapy of tumour diseases. "It is our wish that scientific progress should benefit patients as soon as possible. For this reason we are carrying out our own development work for the implementation of new markers", says Dr Kai Schulze-Forster.

Ineffective therapeutic experiments are thus avoided, as well as difficult questions concerning unclear diagnostic findings. ■

its attractiveness is increasing constantly. The new production facility of Human BioSciences GmbH is the largest foreign location in the Berlin-Brandenburg life sciences business cluster in the past few years. The excellent traffic connections guarantee rapid access to research facilities, universities, partners and international customers. The continuous development of the companies that have settled here bears witness to sound judgement and reliability. The products are innovative and marketable. We, the park's management, support and look after the companies in almost all aspects of their work. You too may convince yourself of our "certified" service and are welcome to join us at any time.

Yours sincerely,

Christoph Weber
Head of the "Biotechnology Park Luckenwalde" Department of the Structural and Economic Development Corporation of the District Teltow-Flaeming ■

mfd Diagnostics GmbH

The mfd Diagnostics GmbH was founded in 2004 and acts as a service provider to the research pharmaceutical industry, biotechnology companies and medical-biological research institutes. The company employs approx. 30 persons in Wendelsheim and, since 2009, 13 people in its development department in Luckenwalde.

At its operational unit in Luckenwalde, which has been located in the Biotechnology Park since 2005, procedures and equipment are being developed for non-invasive intravital diagnostics. For this, the latest, highly innovative, measuring technologies in biophotonics are being used and further developed. We have thereby oriented ourselves especially towards laser spectroscopy: "We are bringing light out of the darkness".

The equipment and processes that are being developed should be applied particularly in

the fields of birth-monitoring, the diagnosis of Alzheimer's and other dementia illnesses as well as cardiovascular illness and for particular forms of therapy, e.g. tumours.

For the purposes of mastering these tasks a team of specialists in laser technology, signal and information processing, equipment development, pharmacy and medicine/biology has been put together. The favourable conditions in the innovative environment of Luckenwalde, which is distinguished in particular by its highly motivated, rapid and efficient service management offered to its resident companies, and the sponsorship of the project by the EU and the State of Brandenburg, were the factors that induced those responsible at mfd Diagnostics to decide in favour of this location. ■



Educational Centre for Biotechnology and Chemistry (BBC)

The ZAL Ludwigfelde GmbH, with its headquarters in Ludwigfelde, took over the training of chemical and biological laboratory assistants in the Biotechnology Park Luckenwalde as of August 1st 2008. The fields of expertise for the future have found a good home in the "Bildungszentrum für Biotechnologie und Chemie" (Educational Centre for Biotechnology and Chemistry.) Despite the financial crisis, experts in these fields are sought in Berlin and Brandenburg. The need for cooperative training specifically tailored

to the requirements of respective companies, is also constantly on the increase. Sixteen future chemical laboratory assistants began their training in the Biotechnology Park on 01 October 2008. Fifteen biological laboratory assistants completed their training in the year 2009, all of them successfully passing the examination. Jobs have already been found for well over 90 % of them. In March 2009 20 people began a retraining course leading to a qualification as a chemical laboratory assistant. In cooperation with the IHK (Chamber of Industry and Commerce) Potsdam and the Arbeitsagentur (Job Centre) Potsdam cooperative training for apprentices and further educational measures for both employees and the unemployed are also being offered to companies in the biotechnology industry by the Centre in its capacity as a service provider for educational services geared to business and industry. Another focal point of the BBC's work is its partnership with schools, in order that pupils might be informed as to the perspectives offered by scientifically oriented professions. ■



Annual DECHEMA - Colloquium

The DECHEMA-colloquium that took place in the Communication Centre at the Biotechnology Park Luckenwalde on 5 November 2009 was already the 12th event of this kind. It was held on the subject of "New Materials for Medicine and Biotechnology - Biopolymers, Synthetic and Biological Surfaces."

An audience of around 100 interested people from regional companies and scientific facilities of the region listened to and took part in the discussion chaired by Dr Waltraud Vorwerg of the Fraunhofer Institute for Applied Research into Polymers in Potsdam concerning current developments and applications in this field. The DECHEMA and BioTOP had once again been able to win over high-ranking speakers from Berlin, Rostock and Mainz for the event. Professor Lendlein of the GKSS Research Centre Geesthacht, Institute for Polymer Research in Teltow began by giving an overview of current trends in polymer systems with tailor-made characteristics or biomedical applications. Professor Haag of the Free University Berlin, Institute for Chemistry and Biochemistry, lectured on the issue of protein-resistant surfaces for the smallest scales in the biochip fields as well as for large-scale application in tankers. The importance of the surface for Lab-on-a-Chip applications was also at the heart of the talk given by Dr Drese from the Institute for Microtechnology in Mainz. Professor Neumann from the DOT GmbH in Rostock inspired his audience with his description of his company's development and the practical application of biomaterials, especially in clinical implants. A lively exchange of experiences held in the foyer of the Communication Centre and accompanied by beer and rolls rounded off a successful colloquium.

All those involved voiced their approval to the organisers that the event had been a success and expressed the wish that the selection of topics for the coming year would be just as interesting. ■

Imprint

Publisher:
Structural and Economic Development Corporation of the District Teltow-Flaeming
Department: Biotechnology Park Luckenwalde
D-14943 Luckenwalde
phone +49 33 71/ 681-100
fax +49 33 71/ 681 105
e-mail: bio-luck@swfg.de, www.bio-luck.de
photos: SWFG mbH, mfd Diagnostics GmbH, CellTrend GmbH, jtv-plan, Hahn, HBS GmbH, ZAL GmbH

production realisation: Werbefactory Luckenwalde